Guidance Issued on Investigational COVID-19 Convalescent Plasma

News
Article

FDA published recommendations on the use of COVID-19 convalescent plasma or investigational convalescent plasma during the pandemic.

On Feb. 11, 2021, FDA published guidance that gives recommendations to health care providers and investigators on the use of COVID-19 convalescent plasma or investigational convalescent plasma. Recommendations are also provided regarding blood collection.The document also discusses the agency’s interim compliance and enforcement policy for investigational new drug requirements for the use of investigational convalescent plasma.

The new guidance, which supersedes guidance issued in January 2021 and previous versions, includes revised recommendations for convalescent plasma donors. “The revisions address when individuals who have received an investigational COVID-19 monoclonal antibody therapy as a participant in a clinical trial, or received an authorized or licensed COVID-19 monoclonal antibody therapy, qualify as convalescent plasma donors,” the guidance states.

Recommendations for qualification and labeling of high titer COVID-19 convalescent plasma under the Emergency Use Authorization have also been revised. The guidance was also updated to “note that FDA intends to exercise enforcement discretion related to the investigational new drug requirements for use of convalescent plasma including when, among other circumstances, the donor meets the qualifications for individuals who have received a COVID-19 vaccine or COVID-19 monoclonal antibody therapy in accordance with section III.B.1 of this guidance.”

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes